CirCode Bio

CirCode Bio is a biotechnology company pioneering the development of circular RNA (circRNA) as a novel class of therapeutics and vaccines. Based on the research of Professor Wensheng Wei from Peking University, the company's platform focuses on the circularization of RNA to enhance stability and prolong protein expression in vivo. This approach aims to overcome the limitations of linear mRNA, such as rapid degradation and the need for high doses. CirCode Bio is advancing a diverse pipeline targeting infectious diseases, including a lead circRNA vaccine for COVID-19, alongside programs in oncology and protein replacement therapies. The company is backed by prominent venture capital firms and operates facilities in Suzhou and Shanghai.